https://www.pharmaceutical-technology.com/data-insights/motixafortide-acetate-biolinerx-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/
Motixafortide acetate is under clinical development by BioLineRx and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).
squamous cell carcinomamotixafortide acetatebiolinerxesophagealescc